Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245689 | 0.92 | TYK2 (0.38) | TYK2PDE4DSTAT3MAP4K1ACKR3 | |
| SCHEMBL24263403 | 0.82 | TYK2 (0.48) | TYK2PDE4DTAS2R14HTT | |
| SCHEMBL20504588 | 0.81 | TYK2 (0.39) | TYK2PDE4D | |
| SCHEMBL16794686 | 0.80 | TYK2 (0.47) | TYK2PDE4D | |
| SCHEMBL22092672 | 0.79 | TYK2 (0.47) | TYK2STAT3KDM4CKDM6BHTT | |
| SCHEMBL30392519 | 0.79 | TYK2 (0.34) | TYK2PDE4D | |
| SCHEMBL26098936 | 0.79 | TYK2 (0.34) | TYK2PDE4D | |
| Potassium SCHEMBL30392983 | 0.79 | TYK2 (0.33) | TYK2PDE4D | |
| SCHEMBL26097378 | 0.79 | TYK2 (0.33) | TYK2PDE4D | |
| SCHEMBL29754423 | 0.79 | TYK2 (0.59) | TYK2PDE4DSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | TYK2, PTK2B, JAK1 | TYK2 1/4885PDE4D 1446/4885STAT3 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.